HealthCert

DermaSensor presents ground-breaking skin cancer technology to GPs and Primary Care Practitioners in Brisbane

BRISBANE, Australia, 13th October 2018: Today, DermaSensor, the medical device company that seeks to enable healthcare professionals to efficiently check for skin cancer, presents its ground-breaking technology concept to GPs and Primary Care Practitioners in Brisbane at HealthCert taking place at the Brisbane Convention & Exhibition Centre.

HealthCert aims to save lives and improve patient outcomes through accredited primary care education. HealthCert is a global organisation dedicated to achieving better patient outcomes through comprehensive GP education and universal access to diagnosis and treatment. More than 10,000 GPs from 32 countries have completed HealthCert programs since 2006.

“As the number one and preferred professional education provider for skin cancer
management and treatment, DermaSensor is delighted to be attending this important training programme conducting market research into the use-case for the DermaSensor device concept. We look forward to building a solid partnership with HealthCert and participating in future education forums,” enthuses Dr. Michael Bonning, Senior Director of Medical Affairs, DermaSensor.

Dr Bonning will be speaking at HealthCert and presenting DermaSensor’s revolutionary, world-first technology concept, designed to augment clinician decision making by providing accurate differentiation between malignant and benign skin lesions to the 200+ delegates in attendance.

This exciting breakthrough was achieved using Elastic Scattering Spectroscopy – a technology pioneered at Boston University and University College London that uses light to evaluate cellular and subcellular structures of the skin. The device is still undergoing FDA and TGA approval and is expected to be available in Australia in late-2020.

DermaSensor aims to improve the way general practitioners assess the skin. The handheld DermaSensor device takes five quick recordings via non-invasive sub-cellular scans. This provides an immediate, objective result that’s typically more accurate than visual assessment alone.

This low-cost, easy-to-use device enables healthcare providers and patients to access fast, accurate skin lesion assessments to ultimately improve outcomes for patients with skin cancer

Its speed and ease of use improves workflow by extending lesion identification and evaluation to trained team members. Patients experience fewer unnecessary complications or side effects and medical practitioners spend less time on lengthy procedures.

Scroll to Top